Click for best price
Tumor Immunotherapy Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Tumor Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunotherapy. This report contains market size and forecasts of Tumor Immunotherapy in global, including the following market information:
Global Tumor Immunotherapy Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Tumor Immunotherapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Tumor Infiltrating Lymphocyte (TIL) Treatment Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Tumor Immunotherapy include Roche, Merck, Novartis, Johnson & Johnson, GlaxoSmithKline, AbbVie, ELI Lilly, Amgen and AstraZeneca, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Tumor Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tumor Immunotherapy Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Tumor Immunotherapy Market Segment Percentages, by Type, 2022 (%)
Tumor Infiltrating Lymphocyte (TIL) Treatment
Engineered T Cell Receptor (TCR) Therapy
Chimeric Antigen Receptor (CAR) T Cell Therapy
Natural Killer (NK) Cell Therapy
Other
Global Tumor Immunotherapy Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Tumor Immunotherapy Market Segment Percentages, by Application, 2022 (%)
Biopharmaceutical Company
Hospital
Universities And Other Scientific Research Institutions
Other
Global Tumor Immunotherapy Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Tumor Immunotherapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumor Immunotherapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Tumor Immunotherapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Merck
Novartis
Johnson & Johnson
GlaxoSmithKline
AbbVie
ELI Lilly
Amgen
AstraZeneca
Bristol-Mysers Squibb
Kite Pharma
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Takara Bio
Unum Therapeutics
Sunway
Junshi Bio
Cinda Bio
BeiGene
Outline of Major Chapters:
Chapter 1: Introduces the definition of Tumor Immunotherapy, market overview.
Chapter 2: Global Tumor Immunotherapy market size in revenue.
Chapter 3: Detailed analysis of Tumor Immunotherapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Tumor Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Tumor Immunotherapy Market, Global Outlook and Forecast 2023-2032 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
111 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Tumor Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Tumor Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Tumor Immunotherapy Overall Market Size
2.1 Global Tumor Immunotherapy Market Size: 2022 VS 2032
2.2 Global Tumor Immunotherapy Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Tumor Immunotherapy Players in Global Market
3.2 Top Global Tumor Immunotherapy Companies Ranked by Revenue
3.3 Global Tumor Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 Tumor Immunotherapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Tumor Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Tumor Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 Tumor Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Tumor Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Tumor Immunotherapy Market Size Markets, 2022 & 2032
4.1.2 Tumor Infiltrating Lymphocyte (TIL) Treatment
4.1.3 Engineered T Cell Receptor (TCR) Therapy
4.1.4 Chimeric Antigen Receptor (CAR) T Cell Therapy
4.1.5 Natural Killer (NK) Cell Therapy
4.1.6 Other
4.2 By Type - Global Tumor Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global Tumor Immunotherapy Revenue, 2018-2023
4.2.2 By Type - Global Tumor Immunotherapy Revenue, 2024-2032
4.2.3 By Type - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Tumor Immunotherapy Market Size, 2022 & 2032
5.1.2 Biopharmaceutical Company
5.1.3 Hospital
5.1.4 Universities And Other Scientific Research Institutions
5.1.5 Other
5.2 By Application - Global Tumor Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global Tumor Immunotherapy Revenue, 2018-2023
5.2.2 By Application - Global Tumor Immunotherapy Revenue, 2024-2032
5.2.3 By Application - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Tumor Immunotherapy Market Size, 2022 & 2032
6.2 By Region - Global Tumor Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global Tumor Immunotherapy Revenue, 2018-2023
6.2.2 By Region - Global Tumor Immunotherapy Revenue, 2024-2032
6.2.3 By Region - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Tumor Immunotherapy Revenue, 2018-2032
6.3.2 US Tumor Immunotherapy Market Size, 2018-2032
6.3.3 Canada Tumor Immunotherapy Market Size, 2018-2032
6.3.4 Mexico Tumor Immunotherapy Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Tumor Immunotherapy Revenue, 2018-2032
6.4.2 Germany Tumor Immunotherapy Market Size, 2018-2032
6.4.3 France Tumor Immunotherapy Market Size, 2018-2032
6.4.4 U.K. Tumor Immunotherapy Market Size, 2018-2032
6.4.5 Italy Tumor Immunotherapy Market Size, 2018-2032
6.4.6 Russia Tumor Immunotherapy Market Size, 2018-2032
6.4.7 Nordic Countries Tumor Immunotherapy Market Size, 2018-2032
6.4.8 Benelux Tumor Immunotherapy Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Tumor Immunotherapy Revenue, 2018-2032
6.5.2 China Tumor Immunotherapy Market Size, 2018-2032
6.5.3 Japan Tumor Immunotherapy Market Size, 2018-2032
6.5.4 South Korea Tumor Immunotherapy Market Size, 2018-2032
6.5.5 Southeast Asia Tumor Immunotherapy Market Size, 2018-2032
6.5.6 India Tumor Immunotherapy Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Tumor Immunotherapy Revenue, 2018-2032
6.6.2 Brazil Tumor Immunotherapy Market Size, 2018-2032
6.6.3 Argentina Tumor Immunotherapy Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Tumor Immunotherapy Revenue, 2018-2032
6.7.2 Turkey Tumor Immunotherapy Market Size, 2018-2032
6.7.3 Israel Tumor Immunotherapy Market Size, 2018-2032
6.7.4 Saudi Arabia Tumor Immunotherapy Market Size, 2018-2032
6.7.5 UAE Tumor Immunotherapy Market Size, 2018-2032
7 Tumor Immunotherapy Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Tumor Immunotherapy Major Product Offerings
7.1.4 Roche Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck Tumor Immunotherapy Major Product Offerings
7.2.4 Merck Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.2.5 Merck Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Tumor Immunotherapy Major Product Offerings
7.3.4 Novartis Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Tumor Immunotherapy Major Product Offerings
7.4.4 Johnson & Johnson Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.4.5 Johnson & Johnson Key News & Latest Developments
7.5 GlaxoSmithKline
7.5.1 GlaxoSmithKline Company Summary
7.5.2 GlaxoSmithKline Business Overview
7.5.3 GlaxoSmithKline Tumor Immunotherapy Major Product Offerings
7.5.4 GlaxoSmithKline Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.5.5 GlaxoSmithKline Key News & Latest Developments
7.6 AbbVie
7.6.1 AbbVie Company Summary
7.6.2 AbbVie Business Overview
7.6.3 AbbVie Tumor Immunotherapy Major Product Offerings
7.6.4 AbbVie Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.6.5 AbbVie Key News & Latest Developments
7.7 ELI Lilly
7.7.1 ELI Lilly Company Summary
7.7.2 ELI Lilly Business Overview
7.7.3 ELI Lilly Tumor Immunotherapy Major Product Offerings
7.7.4 ELI Lilly Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.7.5 ELI Lilly Key News & Latest Developments
7.8 Amgen
7.8.1 Amgen Company Summary
7.8.2 Amgen Business Overview
7.8.3 Amgen Tumor Immunotherapy Major Product Offerings
7.8.4 Amgen Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.8.5 Amgen Key News & Latest Developments
7.9 AstraZeneca
7.9.1 AstraZeneca Company Summary
7.9.2 AstraZeneca Business Overview
7.9.3 AstraZeneca Tumor Immunotherapy Major Product Offerings
7.9.4 AstraZeneca Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.9.5 AstraZeneca Key News & Latest Developments
7.10 Bristol-Mysers Squibb
7.10.1 Bristol-Mysers Squibb Company Summary
7.10.2 Bristol-Mysers Squibb Business Overview
7.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Major Product Offerings
7.10.4 Bristol-Mysers Squibb Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.10.5 Bristol-Mysers Squibb Key News & Latest Developments
7.11 Kite Pharma
7.11.1 Kite Pharma Company Summary
7.11.2 Kite Pharma Business Overview
7.11.3 Kite Pharma Tumor Immunotherapy Major Product Offerings
7.11.4 Kite Pharma Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.11.5 Kite Pharma Key News & Latest Developments
7.12 Adaptimmune
7.12.1 Adaptimmune Company Summary
7.12.2 Adaptimmune Business Overview
7.12.3 Adaptimmune Tumor Immunotherapy Major Product Offerings
7.12.4 Adaptimmune Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.12.5 Adaptimmune Key News & Latest Developments
7.13 Altor Bioscience Corporation
7.13.1 Altor Bioscience Corporation Company Summary
7.13.2 Altor Bioscience Corporation Business Overview
7.13.3 Altor Bioscience Corporation Tumor Immunotherapy Major Product Offerings
7.13.4 Altor Bioscience Corporation Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.13.5 Altor Bioscience Corporation Key News & Latest Developments
7.14 Cellectis
7.14.1 Cellectis Company Summary
7.14.2 Cellectis Business Overview
7.14.3 Cellectis Tumor Immunotherapy Major Product Offerings
7.14.4 Cellectis Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.14.5 Cellectis Key News & Latest Developments
7.15 Juno Therapeutics
7.15.1 Juno Therapeutics Company Summary
7.15.2 Juno Therapeutics Business Overview
7.15.3 Juno Therapeutics Tumor Immunotherapy Major Product Offerings
7.15.4 Juno Therapeutics Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.15.5 Juno Therapeutics Key News & Latest Developments
7.16 Takara Bio
7.16.1 Takara Bio Company Summary
7.16.2 Takara Bio Business Overview
7.16.3 Takara Bio Tumor Immunotherapy Major Product Offerings
7.16.4 Takara Bio Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.16.5 Takara Bio Key News & Latest Developments
7.17 Unum Therapeutics
7.17.1 Unum Therapeutics Company Summary
7.17.2 Unum Therapeutics Business Overview
7.17.3 Unum Therapeutics Tumor Immunotherapy Major Product Offerings
7.17.4 Unum Therapeutics Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.17.5 Unum Therapeutics Key News & Latest Developments
7.18 Sunway
7.18.1 Sunway Company Summary
7.18.2 Sunway Business Overview
7.18.3 Sunway Tumor Immunotherapy Major Product Offerings
7.18.4 Sunway Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.18.5 Sunway Key News & Latest Developments
7.19 Junshi Bio
7.19.1 Junshi Bio Company Summary
7.19.2 Junshi Bio Business Overview
7.19.3 Junshi Bio Tumor Immunotherapy Major Product Offerings
7.19.4 Junshi Bio Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.19.5 Junshi Bio Key News & Latest Developments
7.20 Cinda Bio
7.20.1 Cinda Bio Company Summary
7.20.2 Cinda Bio Business Overview
7.20.3 Cinda Bio Tumor Immunotherapy Major Product Offerings
7.20.4 Cinda Bio Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.20.5 Cinda Bio Key News & Latest Developments
7.21 BeiGene
7.21.1 BeiGene Company Summary
7.21.2 BeiGene Business Overview
7.21.3 BeiGene Tumor Immunotherapy Major Product Offerings
7.21.4 BeiGene Tumor Immunotherapy Revenue in Global Market (2018-2023)
7.21.5 BeiGene Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Tumor Immunotherapy Market Opportunities & Trends in Global Market
Table 2. Tumor Immunotherapy Market Drivers in Global Market
Table 3. Tumor Immunotherapy Market Restraints in Global Market
Table 4. Key Players of Tumor Immunotherapy in Global Market
Table 5. Top Tumor Immunotherapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Tumor Immunotherapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Tumor Immunotherapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Tumor Immunotherapy Product Type
Table 9. List of Global Tier 1 Tumor Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Tumor Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Tumor Immunotherapy Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Tumor Immunotherapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Tumor Immunotherapy Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global Tumor Immunotherapy Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Tumor Immunotherapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Tumor Immunotherapy Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global Tumor Immunotherapy Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Tumor Immunotherapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Tumor Immunotherapy Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America Tumor Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Tumor Immunotherapy Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe Tumor Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Tumor Immunotherapy Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia Tumor Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Tumor Immunotherapy Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America Tumor Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Tumor Immunotherapy Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa Tumor Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Tumor Immunotherapy Revenue, (US$, Mn), 2024-2032
Table 30. Roche Company Summary
Table 31. Roche Tumor Immunotherapy Product Offerings
Table 32. Roche Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 33. Roche Key News & Latest Developments
Table 34. Merck Company Summary
Table 35. Merck Tumor Immunotherapy Product Offerings
Table 36. Merck Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 37. Merck Key News & Latest Developments
Table 38. Novartis Company Summary
Table 39. Novartis Tumor Immunotherapy Product Offerings
Table 40. Novartis Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 41. Novartis Key News & Latest Developments
Table 42. Johnson & Johnson Company Summary
Table 43. Johnson & Johnson Tumor Immunotherapy Product Offerings
Table 44. Johnson & Johnson Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 45. Johnson & Johnson Key News & Latest Developments
Table 46. GlaxoSmithKline Company Summary
Table 47. GlaxoSmithKline Tumor Immunotherapy Product Offerings
Table 48. GlaxoSmithKline Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 49. GlaxoSmithKline Key News & Latest Developments
Table 50. AbbVie Company Summary
Table 51. AbbVie Tumor Immunotherapy Product Offerings
Table 52. AbbVie Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 53. AbbVie Key News & Latest Developments
Table 54. ELI Lilly Company Summary
Table 55. ELI Lilly Tumor Immunotherapy Product Offerings
Table 56. ELI Lilly Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 57. ELI Lilly Key News & Latest Developments
Table 58. Amgen Company Summary
Table 59. Amgen Tumor Immunotherapy Product Offerings
Table 60. Amgen Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 61. Amgen Key News & Latest Developments
Table 62. AstraZeneca Company Summary
Table 63. AstraZeneca Tumor Immunotherapy Product Offerings
Table 64. AstraZeneca Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 65. AstraZeneca Key News & Latest Developments
Table 66. Bristol-Mysers Squibb Company Summary
Table 67. Bristol-Mysers Squibb Tumor Immunotherapy Product Offerings
Table 68. Bristol-Mysers Squibb Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 69. Bristol-Mysers Squibb Key News & Latest Developments
Table 70. Kite Pharma Company Summary
Table 71. Kite Pharma Tumor Immunotherapy Product Offerings
Table 72. Kite Pharma Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 73. Kite Pharma Key News & Latest Developments
Table 74. Adaptimmune Company Summary
Table 75. Adaptimmune Tumor Immunotherapy Product Offerings
Table 76. Adaptimmune Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 77. Adaptimmune Key News & Latest Developments
Table 78. Altor Bioscience Corporation Company Summary
Table 79. Altor Bioscience Corporation Tumor Immunotherapy Product Offerings
Table 80. Altor Bioscience Corporation Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 81. Altor Bioscience Corporation Key News & Latest Developments
Table 82. Cellectis Company Summary
Table 83. Cellectis Tumor Immunotherapy Product Offerings
Table 84. Cellectis Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 85. Cellectis Key News & Latest Developments
Table 86. Juno Therapeutics Company Summary
Table 87. Juno Therapeutics Tumor Immunotherapy Product Offerings
Table 88. Juno Therapeutics Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 89. Juno Therapeutics Key News & Latest Developments
Table 90. Takara Bio Company Summary
Table 91. Takara Bio Tumor Immunotherapy Product Offerings
Table 92. Takara Bio Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 93. Takara Bio Key News & Latest Developments
Table 94. Unum Therapeutics Company Summary
Table 95. Unum Therapeutics Tumor Immunotherapy Product Offerings
Table 96. Unum Therapeutics Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 97. Unum Therapeutics Key News & Latest Developments
Table 98. Sunway Company Summary
Table 99. Sunway Tumor Immunotherapy Product Offerings
Table 100. Sunway Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 101. Sunway Key News & Latest Developments
Table 102. Junshi Bio Company Summary
Table 103. Junshi Bio Tumor Immunotherapy Product Offerings
Table 104. Junshi Bio Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 105. Junshi Bio Key News & Latest Developments
Table 106. Cinda Bio Company Summary
Table 107. Cinda Bio Tumor Immunotherapy Product Offerings
Table 108. Cinda Bio Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 109. Cinda Bio Key News & Latest Developments
Table 110. BeiGene Company Summary
Table 111. BeiGene Tumor Immunotherapy Product Offerings
Table 112. BeiGene Tumor Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 113. BeiGene Key News & Latest Developments
List of Figures
Figure 1. Tumor Immunotherapy Segment by Type in 2022
Figure 2. Tumor Immunotherapy Segment by Application in 2022
Figure 3. Global Tumor Immunotherapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Tumor Immunotherapy Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Tumor Immunotherapy Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Tumor Immunotherapy Revenue in 2022
Figure 8. By Type - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 9. By Application - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 10. By Type - Global Tumor Immunotherapy Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 12. By Application - Global Tumor Immunotherapy Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 14. By Region - Global Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 15. By Country - North America Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 16. US Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 17. Canada Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 20. Germany Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 21. France Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 23. Italy Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 24. Russia Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 28. China Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 29. Japan Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 32. India Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 34. Brazil Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa Tumor Immunotherapy Revenue Market Share, 2018-2032
Figure 37. Turkey Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 38. Israel Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 40. UAE Tumor Immunotherapy Revenue, (US$, Mn), 2018-2032
Figure 41. Roche Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Novartis Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Johnson & Johnson Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. GlaxoSmithKline Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. AbbVie Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. ELI Lilly Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Amgen Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. AstraZeneca Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Bristol-Mysers Squibb Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Kite Pharma Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Adaptimmune Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Altor Bioscience Corporation Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Cellectis Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Juno Therapeutics Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Takara Bio Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Unum Therapeutics Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Sunway Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. Junshi Bio Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Cinda Bio Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 61. BeiGene Tumor Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
